In Vitro ADMET Laboratories LLC Announces Novel QuickRefreeze Technology for the Preparation of Cryopreserved Human Hepatocytes Pooled from Multiple Donors

Share Article

A novel technology, the QuickRefreeze technology (patent pending), has been developed by In Vitro ADMET Laboratories for the preparation of cryopreserved human hepatocytes pooled from multiple donors using previously cryopreserved hepatocytes from single donors. The technology eliminates procedures used to enrich for viable hepatocytes before recryopreservation.

In Vitro ADMET Laboratories LLC (IVAL) is proud to announce successful preparation of cryopreserved human hepatocytes from multiple donors using a novel QuickRefreeze technology. This technology (patent pending) involves thawing of previously cryopreserved human hepatocytes prepared from individual donors, followed by rapid pooling at cold temperature and immediate re-cryopreservation. The uniqueness of the technology is the elimination of the time-consuming, laborious, and potentially damaging procedures used to enrich for viable hepatocytes such as density gradient separation or elutriation before refreezing.

“This is a surprise finding," says Dr. Albert P. Li, Ph. D., Founder, President and C. E. O. of IVAL. “I was always concerned with the potentially damaging effects of freezing hepatocytes more than once. We have discovered that using the QuickRefreeze technology, the twice-cryopreserved hepatocyte preparations would retain viability and metabolic enzyme activities similar to that measured before the second freezing." Dr. Li stated that this QuickRefreeze method can be used to prepare cryopreserved human hepatocytes pooled from multiple donors. Pooled hepatocytes from multiple donors can be used to evaluate drug properties such as drug metabolism, drug-drug interactions, and drug toxicity.

Dr. Li (Ph. D., Biomedical Sciences), is a world-renowned expert in the application of human-based in vitro experimental systems for the evaluation of drug properties. He was one of the pioneers in hepatocyte cryopreservation.

About In Vitro ADMET Laboratories LLC (IVAL)
IVAL was established by Dr. Albert P. Li in 2004. The company produces research reagents and provides contract research services to aid drug discovery and drug development, focusing on in vitro evaluation of drug metabolism, drug-drug interactions, and drug toxicity. IVAL is the world’s leading company in hepatocyte technologies, with widely-acclaimed hepatocyte products including high quality plateable cryopreserved human hepatocytes as well as plateable cryopreserved mouse, rat, dog, and monkey hepatocytes. IVAL is located in Columbia, Maryland. Further information concerning IVAL can be obtained at the company website: http://www.invitroadmet.com or contact IVAL at info(at)invitroadmet(dot)com (tel. (410)869-9037).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website